Authorizes medical cannabis for treatment of sickle cell anemia.

S 2392 amends New Jersey's existing medical cannabis law to add sickle cell anemia as a qualifying condition for treatment. This allows patients diagnosed with sickle cell anemia to access medical cannabis under the state's current program, following the same registration and physician authorization process as other qualifying conditions. The bill expands the list of approved medical conditions without creating new infrastructure or changing dispensary rules. It directly affects sickle cell anemia patients seeking alternative treatment options within New Jersey's regulated medical cannabis system. The policy change integrates sickle cell anemia into the existing framework established by P.L.2009, c.307.